Choose your Region

Are you sure you want to proceed?

You will be leaving the Cook Medical website that you were viewing and going to a Cook Medical website for another region or country. Not all products are approved in all regulatory jurisdictions. The product information on these websites is intended only for licensed physicians and healthcare professionals.

Newsroom
January 15th, 2020

Cook Medical TriForce® Peripheral Crossing Set now available


Cook Medical's TriForce® Peripheral Crossing Set

Cook Medical’s TriForce® Peripheral Crossing Set

Bloomington, Ind. – Cook Medical’s TriForce® Peripheral Crossing Set is now commercially available. As of January 2020, these products are available to physicians in the United States to support procedures to treat patients with vascular obstructions.

The TriForce Peripheral Crossing Set is designed to be percutaneously introduced into blood vessels and support a wire guide while performing a peripheral intervention. This device is also intended for injection of radiopaque contrast media for the purpose of angiography. TriForce is offered in two lengths and four configurations, which means physicians have several product options to treat blocked or restricted vessels in a variety of locations in the body.

Mark Breedlove, vice president of Cook Medical’s Vascular division, said, “We are excited to have this tool available for our physicians to treat complex peripheral vascular disease.”

To learn more about TriForce products, see the product page here.

About Cook Medical
Since 1963, Cook Medical has worked closely with physicians to develop technologies that eliminate the need for open surgery. Today we are combining medical devices, biologic materials and cellular therapies to help the world’s healthcare systems deliver better outcomes more efficiently. We have always remained family owned so that we have the freedom to focus on what we care about: our patients, our employees, and our communities. Find out more at CookMedical.com, and for the latest news, follow us on Twitter, Facebook and LinkedIn.